A shift in microglial β-amyloid binding in Alzheimer's disease is associated with cerebral amyloid angiopathy

Matthew Zabel1, Matthew Schrag, Andrew Crofton

  • 1Neurosurgery Center for Research, Training and Education, Loma Linda University, Loma Linda, CA 92354, USA.

Insights

Alzheimer's disease and cerebral amyloid angiopathy involve beta-amyloid (Aβ) buildup. This study shows microglia-associated Aβ clearance mechanisms may drive Aβ deposition and complement activation in cerebral amyloid angiopathy.

Area of Science:

  • Neuroscience
  • Immunology
  • Neuropathology

Background:

  • Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) are common neurodegenerative pathologies characterized by beta-amyloid (Aβ) accumulation and neuroinflammation.
  • The precise mechanisms underlying Aβ clearance and the role of the complement system in these conditions remain incompletely understood.

Purpose of the Study:

  • To investigate the differential expression of microglia-associated Aβ ligands in post-mortem human brains.
  • To examine the association of these ligands with complement activation in AD with and without concomitant CAA.

Main Methods:

  • Analysis of human post-mortem brain homogenates and microvessel fractions from AD subjects (with and without CAA) and age-matched controls.
  • Quantification of C3b, membrane attack complex (MAC), CD11b, and α-2-macroglobulin.
  • Immunoprecipitation (IP) to detect CD11b/C3b/Aβ complexes and confocal microscopy to visualize interactions.

Main Results:

  • Significantly elevated levels of C3b and MAC were observed in brains with CAA compared to AD-only and control groups.
  • Immunoprecipitation revealed increased CD11b/C3b complexes with Aβ in subjects with both AD and CAA.
  • MAC was notably associated with CAA-affected blood vessels, unlike in AD-only or control vessels.

Conclusions:

  • Findings suggest a microglial CD11b-mediated Aβ clearance pathway that transports Aβ and C3b to blood vessels in AD/CAA.
  • This process may contribute to Aβ deposition and complement propagation, leading to MAC formation and potential vascular fragility.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...